Overview

Anticoagulation-free VV ECMO for Acute Respiratory Failure

Status:
Not yet recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
Currently international experts recommend therapeutic anticoagulation for veno-venous extracorporeal membrane oxygenation (VV-ECMO). Reports and case series suggest that the absence of therapeutic anticoagulation is safe for VV-ECMO. No randomized control trials have assessed this. The aim of this pilot study is to assess safety and feasibility of an "anticoagulation-free strategy" for veno-venous ECMO (VV-ECMO) in Acute respiratory distress syndrome (ARDS).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Damian Ratano
Collaborator:
The Physicians' Services Incorporated (PSI) Foundation
Treatments:
Calcium heparin
Enoxaparin
Heparin